Omeros falls 10% despite revenue beat
Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.
How this was made
The 30-second read
Why it matters
The immediate tradable signal is the divergence between adjusted profitability and GAAP loss, with the after-hours selloff indicating investors are penalizing accounting volatility and/or balance-sheet risk even amid revenue growth.
Market read
Traders should focus on the after-hours reaction and the stated driver of the GAAP loss, since it can dominate near-term sentiment despite adjusted beat and positive cash flow.
What to watch
Gross-to-net adjustment rose to 14.0% from 11.5%, and 340B participation increased; both could affect future margins and investor confidence beyond the headline GAAP loss.
Background
Omeros’ Q3 included YARTEMLEA growth and positive operating cash flow, but GAAP results deteriorated due to a large non-cash derivative loss tied to convertible notes.
Ticker impact
Omeros reported Q3 revenue of $41.8M and adjusted EPS of $0.06, but shares fell 10% after-hours on a widened GAAP net loss tied to convertible-note derivatives.
Likely continued pressure or choppy trading as investors weigh adjusted outperformance against the widened GAAP loss and derivative-driven volatility.
The article directly links the after-hours 10% drop to the widened GAAP net loss and specifies the non-cash $62.0M derivative mark-to-market driver.
Market effects
Highlights how biotech investors may discount adjusted beats when GAAP losses widen due to non-cash derivative accounting, potentially increasing sensitivity to balance-sheet/convertible structures.
Limited, as the catalyst is company-specific and US-listed trading.
Moderate for European regulatory sentiment, since the article references a prior EMA negative opinion on narsoplimab.
Counterpoint
The GAAP loss is largely non-cash derivative mark-to-market, while operating cash flow was positive and YARTEMLEA revenue grew sequentially, which may support a rebound if investors refocus on cash generation.
Key entities
- companyOmeros Corporation
NASDAQ-listed biotech whose Q3 beat was offset by a widened GAAP net loss and a 10% after-hours share drop.
- productYARTEMLEA
Omeros’ approved stem cell transplant-associated thrombotic microangiopathy treatment; generated $41.8M gross revenue in Q3.
- regulatorEuropean Medicines Agency (CHMP)
Issued a negative opinion on Omeros’ narsoplimab marketing authorization application in TA-TMA after re-examination.


